Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Oct 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called sodium glycididazole, which is being tested to see if it can help reduce the side effects of combined chemotherapy and radiation therapy in patients with a certain type of lung cancer. Specifically, the trial focuses on people who have non-small cell lung cancer that cannot be surgically removed and who have already undergone initial chemotherapy and radiation treatment.

To participate in this trial, patients need to have a confirmed diagnosis of non-small cell lung cancer at an advanced stage (stage II-III) and should be in reasonably good health, meaning they have a certain level of physical fitness and organ function. The study is currently looking for participants aged between 65 and 75, and it is open to all genders. If eligible, participants can expect to receive the new treatment while also undergoing the standard chemotherapy and radiation therapy, and they will be monitored closely for any side effects or improvements in their condition. Remember, this trial is still recruiting participants, so if you or someone you know is interested, it might be worth discussing with a healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients must have histologically or cytologically confirmed non-small cell lung cancer.
• • 2. Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.
• • 3. ECOG PS 0-2
• • 4. Adequate organ and bone marrow function.
• Exclusion Criteria:
• • 1. History of previous radiotherapy.
• • 2. The previous immune-related pneumonitis ≥ grade 2.
• • 3. Local lesions require surgery.
• • 4. History of another primary malignancy.
• • 5. History of active primary immunodeficiency.
• • 6. Histological findings showed mixed small cell lung cancer and non-small cell lung cancer.
• • 7. For any unmitigated toxicity during pre-study chemoradiotherapy.